Parametric Portfolio Associates LLC Grows Stake in Express Scripts Holding Company (ESRX)

Parametric Portfolio Associates LLC grew its position in Express Scripts Holding Company (NASDAQ:ESRX) by 25.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,551,526 shares of the company’s stock after acquiring an additional 317,878 shares during the quarter. Parametric Portfolio Associates LLC owned about 0.27% of Express Scripts worth $98,243,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Dodge & Cox lifted its position in Express Scripts by 25.7% during the second quarter. Dodge & Cox now owns 36,188,517 shares of the company’s stock worth $2,310,275,000 after buying an additional 7,388,021 shares in the last quarter. Macquarie Group Ltd. lifted its position in Express Scripts by 8.4% during the second quarter. Macquarie Group Ltd. now owns 11,880,919 shares of the company’s stock worth $758,480,000 after buying an additional 922,406 shares in the last quarter. Northern Trust Corp lifted its position in Express Scripts by 12.2% during the second quarter. Northern Trust Corp now owns 11,068,777 shares of the company’s stock worth $706,629,000 after buying an additional 1,206,980 shares in the last quarter. Veritas Asset Management LLP lifted its position in Express Scripts by 5.6% during the third quarter. Veritas Asset Management LLP now owns 8,652,910 shares of the company’s stock worth $547,902,000 after buying an additional 460,338 shares in the last quarter. Finally, Nordea Investment Management AB lifted its position in Express Scripts by 2.6% during the third quarter. Nordea Investment Management AB now owns 7,304,973 shares of the company’s stock worth $462,551,000 after buying an additional 188,528 shares in the last quarter. Institutional investors and hedge funds own 88.44% of the company’s stock.

In other news, VP Phyllis S. Anderson sold 643 shares of Express Scripts stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $62.37, for a total value of $40,103.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Timothy C. Wentworth acquired 8,000 shares of the company’s stock in a transaction dated Tuesday, October 31st. The stock was purchased at an average cost of $61.13 per share, with a total value of $489,040.00. Following the completion of the purchase, the chief executive officer now directly owns 98,628 shares of the company’s stock, valued at approximately $6,029,129.64. The disclosure for this purchase can be found here. Insiders own 0.68% of the company’s stock.

A number of equities analysts recently commented on ESRX shares. ValuEngine downgraded Express Scripts from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Robert W. Baird reiterated a “hold” rating and set a $56.00 price objective on shares of Express Scripts in a research report on Friday, September 1st. Jefferies Group set a $72.00 target price on Express Scripts and gave the stock a “buy” rating in a research note on Tuesday, August 29th. Raymond James Financial reissued an “underperform” rating on shares of Express Scripts in a research note on Monday, October 9th. Finally, Zacks Investment Research cut Express Scripts from a “buy” rating to a “sell” rating in a research note on Tuesday, October 24th. Five investment analysts have rated the stock with a sell rating, ten have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Express Scripts presently has an average rating of “Hold” and a consensus price target of $74.40.

Shares of Express Scripts Holding Company (ESRX) opened at $71.55 on Friday. Express Scripts Holding Company has a one year low of $55.80 and a one year high of $73.42. The company has a quick ratio of 0.61, a current ratio of 0.73 and a debt-to-equity ratio of 0.86. The firm has a market capitalization of $40,523.99, a price-to-earnings ratio of 10.46, a PEG ratio of 1.06 and a beta of 0.88.

Express Scripts (NASDAQ:ESRX) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.90 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $1.90. Express Scripts had a return on equity of 25.46% and a net margin of 3.64%. The business had revenue of $24.68 billion during the quarter, compared to analysts’ expectations of $25.68 billion. During the same period in the previous year, the firm posted $1.74 earnings per share. The company’s revenue was down 2.9% on a year-over-year basis. sell-side analysts predict that Express Scripts Holding Company will post 7.02 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://stocknewstimes.com/2017/12/17/parametric-portfolio-associates-llc-grows-stake-in-express-scripts-holding-company-esrx.html.

Express Scripts Profile

Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).

Institutional Ownership by Quarter for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply